Ocular gene therapy for neovascular AMD: a new era?

Affiliations

¹ 2nd Department of Ophthalmology, National and Kapodistrian University of Athens, Athens 12462, Greece. Electronic address: eirchat@yahoo.gr.
² Department of Epidemiology and Biostatistics, National and Kapodistrian University of Athens, Athens 12462, Greece.

Comment

Irini P Chatziralli et al. Lancet. 2017.

. 2017 Nov 11;390(10108):2139-2140.

doi: 10.1016/S0140-6736(17)32447-9. Epub 2017 Nov 9.

¹ 2nd Department of Ophthalmology, National and Kapodistrian University of Athens, Athens 12462, Greece. Electronic address: eirchat@yahoo.gr.
² Department of Epidemiology and Biostatistics, National and Kapodistrian University of Athens, Athens 12462, Greece.

No abstract available

Comment in

Ocular gene therapy for neovascular AMD: a new era? - Authors' reply.
Campochiaro PA, Heier JS, Kherani S, Le-Halpere A, Scaria A. Campochiaro PA, et al. Lancet. 2017 Nov 11;390(10108):2140. doi: 10.1016/S0140-6736(17)32424-8. Epub 2017 Nov 9. Lancet. 2017. PMID: 29143750 No abstract available.

Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial.
Heier JS, Kherani S, Desai S, Dugel P, Kaushal S, Cheng SH, Delacono C, Purvis A, Richards S, Le-Halpere A, Connelly J, Wadsworth SC, Varona R, Buggage R, Scaria A, Campochiaro PA. Heier JS, et al. Lancet. 2017 Jul 1;390(10089):50-61. doi: 10.1016/S0140-6736(17)30979-0. Epub 2017 May 17. Lancet. 2017. PMID: 28526489 Clinical Trial.